Table 4.
DNA or RNA based vaccines, clinical trial
| Vaccines types | Strategy of Design | Clinical Phase |
|---|---|---|
| mRNA-1273 | A lipid nanoparticle–encapsulated, nucleoside-modified messenger RNA that encodes the spike glycoprotein | Phases1/2, 2, 2/3 and 4 |
| BNT162b2 | Nucleoside-modified RNA, contained within a lipid nanoparticle, which encodes the full-length spike | Phases1/2, 2, 2/3 and 4 |
| CVnCoV Vaccine | An optimized, non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein, formulated within Lipid Nano-particles (LNPs) | Phases 2, 2/3, 3 |
| ARCT-021 | self-transcribing and replicating mRNA (STARR™) with LUNAR® lipid-mediated delivery technology | Phases1/2, 2 |
| LNP-nCoVsaRNA | A purified, synthetic mRNA vaccine candidate encoding the S glycoprotein | Phase 1 |
| SARS-CoV-2 mRNA vaccine (ARCoV) | A nucleoside-modified mRNA vaccine in lipid-encapsulated form that encoded the SARS-CoV-2 RBD (mRNA-RBD) | Phases 1, 2, 3 |
| ChulaCov19 mRNA vaccine | SARS-Cov2 Wild-type S-spike mRNA/lipid nanoparticle (LNP) vaccine | Phase 1 |
| CoV2 SAM (LNP) vaccine. | A self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform + Spike antigen | Phase 1 |
| mRNA-1273.351. | A lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant | Phase 1, 2, 4 |
| MRT5500, | An mRNA vaccine candidate | Phase 1/2 |
| HDT-301 | Self-replicating mRNA vaccine formulated as a lipid nanoparticle | Phase 1 |
| Covigenix VAX-001 | DNA vaccines + proteo-lipid vehicle (PLV) formulation | Phase 1 |
| CORVax | Spike (S) Protein Plasmid DNA Vaccine | Phase 1 |
| bacTRL | Spike oral DNA vaccine | Phase 1 |
| COVID-eVax | A candidate plasmid DNA vaccine of the Spike protein | Phase 1/2 |
Source: ClinicalTrials.gov website; Covid19.trackvaccines.org, WHO.